Overview
- Fourth-quarter revenue was $17.5 million, down 6% year over year but above the $17.09 million consensus, with adjusted EPS of $0.10 versus an expected loss of $0.05 and $0.18 a year ago.
- Software revenue fell 9% to $9.0 million and services declined 3% to $8.4 million; gross profit was $9.8 million (56% margin) and adjusted EBITDA was $3.5 million (20% of revenue) versus 22% a year earlier.
- Fiscal 2026 guidance was reaffirmed at $79 million to $82 million in revenue, adjusted EPS of $1.03 to $1.10, and an adjusted EBITDA margin of 26% to 30%.
- Shares rose about 18% intraday to $20.26 following the results and guidance update.
- William Blair highlighted signs of demand stabilization as biotech funding improves and large‑pharma concerns ease, noted investments in AI and product unification, reiterated Outperform, and cautioned that the timing of a sustained rebound remains uncertain.